72479-06-2

Basic information

• Product Name: (S)-5-OXO-2-PYRROLIDINEACETONITRILE
• Synonyms: (S)-5-OXO-2-PYRROLIDINEACETONITRILE;(2S)-5-oxo-2-Pyrrolidineacetonitrile;(S)-(5-Oxo-pyrrolidin-2-yl)-acetonitrile;[(2S)-5-oxo-2-pyrrolidinyl]acetonitrile
• CAS NO: 72479-06-2
• Molecular Formula: C₆H₈N₂O
• Molecular Weight: 124.14
• Mol File: 72479-06-2.mol

Chemical Properties

• Melting Point: 81-83 °C(Solv: benzene (71-43-2); ethyl ether (60-29-7))
• Boiling Point: 399.7±15.0 °C(Predicted)
• Appearance: /
• Density: 1.106±0.06 g/cm3(Predicted)
• PKA: 15.39±0.40(Predicted)
• CAS DataBase Reference: (S)-5-OXO-2-PYRROLIDINEACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-5-OXO-2-PYRROLIDINEACETONITRILE(72479-06-2)
• EPA Substance Registry System: (S)-5-OXO-2-PYRROLIDINEACETONITRILE(72479-06-2)

Safety Data

• Hazardous Substances Data: 72479-06-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(S)-5-OXO-2-PYRROLIDINEACETONITRILE is used as a key component in the development of various pharmaceutical drugs and active ingredients. Its unique chemical structure and reactivity contribute to its importance in this field.
Used in Organic Synthesis:
In the realm of organic synthesis, (S)-5-OXO-2-PYRROLIDINEACETONITRILE serves as a vital building block, facilitating the creation of a diverse array of chemical compounds.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
(S)-5-OXO-2-PYRROLIDINEACETONITRILE is also utilized as a chiral auxiliary, playing a crucial role in asymmetric synthesis. This application underscores its versatility and the breadth of its potential uses in chemical and pharmaceutical research.

Upstream product

• 51693-17-5 (S)-toluene-4-sulfonic acid 5-oxo-pyrrolidin-2-ylmethyl ester 
• 773837-37-9 sodium cyanide 
• 4931-66-2 methyl (S)-pyroglutamate 
• 93288-20-1 [(2S)-5-oxopyrrolidin-2-yl]methyl methanesulfonate 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 56-86-0 L-glutamic acid 
• 17342-08-4 (S)-Pyroglutaminol 
• 143-33-9 sodium cyanide 
• 151-50-8 potassium cyanide 
• 98-79-3 L-Pyroglutamic acid 
• 72479-05-1 (S)-(-)-5-(Bromomethyl)-2-pyrrolidinone 

Downstream Products

• 149427-84-9 (S)-5-(2-hydroxy-ethyl)-pyrrolidin-2-one 
• 936114-10-2 methyl 5-nitro-2-[(5S)-5-{[(tert-butyl)dimethylsilyloxyethyl]}-2-oxo-1-pyrrolidinyl]benzoate 
• 936114-41-9 methyl 5-amino-2-[(5S)-5-{[(tert-butyl)dimethylsilyiloxyethyl]}-2-oxo-1-pyrrolidinyl]benzoate 
• 936114-46-4 methyl 5-iodo-2-[(5S)-5-(hydroxyethyl)-2-oxo-1-pyrrolidinyl]benzoate 
• 936114-30-6 methyl 5-iodo-2-[(5S)-5-(ethenyl)-2-oxo-1-pyrrolidinyl]benzoate 
• 936114-93-1 (5S)-5-ethenyl-1-[4-iodo-2-(hydroxymethyl)phenyl]-2-pyrrolidinone 
• 936114-51-1 (5S)-5-ethenyl-1-[4-iodo-2-formylphenyl]-2-pyrrolidinol 
• 124201-75-8 (S)-(5-oxo-pyrrolidin-2-yl)-acetic acid ethyl ester 
• 173472-45-2 [(S)-5-Oxo-1-(toluene-4-sulfonyl)-pyrrolidin-2-yl]-acetonitrile 
• 202532-13-6 N-[(S)-1-(2-{3-[(S)-3-(tert-Butyl-dimethyl-silanyloxy)-1-(2-methylsulfanyl-ethyl)-propyl]-thioureido}-ethyl)-4-(tert-butyl-diphenyl-silanyloxy)-butyl]-4-methyl-benzenesulfonamide 
• 173472-40-7 N-[(S)-4-(tert-Butyl-diphenyl-silanyloxy)-1-(2-{3-[(R)-1-(2-methylsulfanyl-ethyl)-3-triethylsilanyloxy-propyl]-thioureido}-ethyl)-butyl]-4-methyl-benzenesulfonamide 
• 173472-41-8 (2S,8S)-2-[3-(tert-Butyl-diphenyl-silanyloxy)-propyl]-1-(toluene-4-sulfonyl)-8-(2-triethylsilanyloxy-ethyl)-1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine 
• 173472-38-3 N-[(S)-1-(2-Amino-ethyl)-4-(tert-butyl-diphenyl-silanyloxy)-butyl]-4-methyl-benzenesulfonamide 
• 173472-46-3 (S)-5-Cyano-4-(toluene-4-sulfonylamino)-pentanoic acid methyl ester 

Relevant articles and documents

NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

Described herein are new, selective modulators of the 5 -HT7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors

Synthesis of optically active (R)- And (S)-β-arginine from pyroglutamic acid

– The first synthesis of optically active β-arginine was achieved starting from commercially available pyroglutamic acid. The new synthetic protocol is characterized by the use of nitrile as a carboxylic acid surrogate which could be transformed to the co

NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5- hydroxytryptamine receptor 7 activity. A is selected

BETA-LACTAMASE INHIBITOR COMPOUNDS

The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta- lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.

Total synthesis of (-)-martinellic acid

An enantioselective formal total synthesis of the pyrrolo[3,2-c]quinoline natural product martinellic acid has been achieved. The key steps involve a Pd-catalyzed aryl amidation reaction of a pyrroglutamate derivative, an intramolecular [3+2] azomethine ylide-alkene cycloaddition and a reductive ring opening reaction.

Total synthesis of (+)-batzelladine A and (-)-batzelladine D via [4 + 2]-annulation of vinyl carbodiimides with N-alkyl imines

A diastereoselective [4 + 2]-annulation of vinyl carbodiimides with chiral N-alkyl imines has been developed to access the stereochemically rich polycyclic guanidine cores of the batzelladine alkaloids. Application of this strategy, together with additional key steps such as long-range directed hydrogenation and diastereoselective intramolecular iodo-amination, led to highly convergent total syntheses of (-)-batzelladine D and (+)-batzelladine A with excellent stereocontrol.

The synthesis of di(hydroxyalkyl) substituted bicyclic guanidines

The synthesis of the enantiomerically pure bicyclic guanidines 3a and 3b is described.The convergent strategy is based on methodology developed by Schmidtchen.The therefore required amine components 6 and 9 obtained from methionine and L-glutamic acid, respectively.

Synthesis of a Chiral Di(hydroxyalkyl) Substituted Bicyclic Guanidine

Schmidtchen's methodology is used successfully for the synthesis of the chiral disubstituted bicyclic guanidinium salt 2.The two therefore required primary amine compounds 6 and 9 are obtained from L-methionine and L-glutamic acid, respectively.

Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor

4-Amino-5-hexenoic acid is prepared by: (a) reacting 5-oxo-2-pyrrolidine-acetonitrile with hydrogen and dimethylamine in the presence of a palladium catalyst to form N,N-dimethyl-2-[5'-oxo-2'-pyrrolidine]ethylamine; (b) oxidizing N,N-dimethyl-2-[5'-oxo-2'-pyrrolidine]-ethylamine to produce the corresponding N-oxide derivative; (c) pyrolysis of the N-oxide derivative to form 5-vinyl-2-pyrrolidinone; (d) optionally, separating N,N-dimethyl-2-[5'-oxo-2'-pyrrolidine]ethylamine by-product from the 5-vinyl-2-pyrrolidinone product; and (e) hydrolyzing 5-vinyl-2-pyrrolidinone to form 4-amino-5-hexenoic acid.